查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541318

2024-2032 年按產品、手術類型、最終用戶和地區分類的脊椎生物製劑市場報告

Spine Biologics Market Report by Product, Surgery Type, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球脊椎生物製品市場規模達21億美元。該市場的推動因素包括微創手術 (MIS) 的廣泛採用、老年人口的不斷成長、收入水平上漲導致醫療服務的機會不斷增加以及脊椎疾病發病率的增加。

脊椎生物製品市場分析：

主要市場促進因素：脊椎生物製劑市場研究表明，該市場主要是由椎間盤疾病和椎管狹窄等脊椎疾病日益流行所驅動，這些疾病通常與老化和生活方式因素有關。

主要市場趨勢：在脊椎手術中使用生物製劑以促進更快的恢復和更好的結果，與醫療技術的進步保持一致，是一個明顯的趨勢。在脊椎生物製劑市場預測中，業界將見證人工智慧和機器學習技術相結合的持續創新，以提高脊椎生物製劑的精確度和有效性。

地理趨勢：由於其先進的醫療基礎設施、高額醫療支出和對脊椎疾病的認知，北美目前引領全球市場。此外，根據脊椎生物製品市場統計數據，由於醫療保健機會的增加、經濟標準的提高以及老年人口的增加，亞太地區正在經歷快速成長。

競爭格局：脊椎生物製劑產業的一些主要市場參與者包括 Arthrex Inc.、Alphatec Holdings Inc.、Exactech Inc.、Johnson & Johnson、Medtronic plc、NuVasive Inc.、Orthofix Medical Inc.、Stryker Corporation、Wright Medical Group NV 、Zimmer Biomet 等。

挑戰與機會：市場面臨的挑戰包括對生物製品高成本的擔憂以及可能延遲產品上市的嚴格監管環境。正如脊椎生物製劑市場概述中所述，與保險提供者和醫療保健機構不斷加強的合作有可能改善生物治療的取得和採用，從而產生大量機會。

脊椎生物製劑市場趨勢：

脊椎疾病的盛行率不斷增加

脊椎疾病的日益增多正在影響脊椎生物製劑市場的成長。此外，預期壽命的延長和生活方式問題正在刺激椎間盤疾病和椎管狹窄等退化性疾病的發展。根據世界衛生組織(WHO) 的數據，2020 年，大約每13 個人中就有1 人（即6.19 億人）經歷過腰痛(LBP)，比1990 年增加了60%。約843 例到 2050 年，這一數字將達到 100 萬，這強調了脊椎問題的廣泛性。發病率隨80歲年齡層增加而增加，其中50-55歲年齡層發生率增加。這種廣泛的盛行率需要持續開發和部署有效的治療方法，包括生物製劑，這有助於促進骨骼生長和癒合，這使得它們對於治療這些普遍性疾病至關重要。

微創手術 (MIS) 的採用率不斷上升

脊椎疾病的微創手術 (MIS) 是首選，因為與傳統的開放性手術相比，其痛苦較小且恢復時間較快。根據 IMARC GROUP 的數據，2024 年至 2032 年期間，全球微創手術市場預計將以約 6% 的年複合成長率(CAGR) 擴張。 2023 年達到 529 億美元，預計到 2032 年市場將達到 910 億美元。 這種成長宣告了手術方法的轉變，減少了住院時間和恢復時間，這對脊椎生物製品的市場價值特別有利。

老年人口不斷增加

不斷成長的老年人口正在推動脊椎生物製劑市場需求。隨著年齡的成長，脊椎疾病的風險增加，需要更頻繁和更深入的護理。根據聯合國的資料，65 歲及以上人口預計將從 2022 年的 10% 上升至 2050 年的 16%。兒童的數量。這意味著與年齡相關的脊椎疾病數量不斷增加，對有效且微創治療的需求不斷增加。例如，有助於自然癒合過程的生物製劑特別適合滿足這些需求，符合全球人口老化日益成長的醫療保健需求。

脊椎生物製品市場細分：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據產品、手術類型和最終用戶對市場進行了分類。

按產品分類：

同種異體脊椎移植物

機械加工骨同種異體移植物

去礦骨基質

骨移植替代品

骨形態發生蛋白

合成骨移植物

基於細胞的矩陣

骨移植替代品佔大部分市場佔有率

該報告根據產品提供了詳細的市場細分和分析。這包括脊椎同種異體移植物（機械加工的同種異體骨移植、脫礦骨基質）、骨移植替代品（骨形態發生蛋白、合成骨移植物）和以細胞為基礎的基質。根據該報告，骨移植替代品佔最大部分。

骨移植替代品提供了傳統骨移植的替代方案，規定了脊椎手術中的結構支撐並促進骨癒合過程。這些替代品包括合成材料、同種異體移植物和脫礦骨基質，並因其能夠支持骨融合並抑制從患者自身採集骨骼的需要而受到提倡，從而最大限度地減少手術併發症和恢復時間。根據IMARC GROUP統計，2023年全球骨移植和替代品市場規模達32億美元，預計到2032年將達到51億美元，2024-2032年年複合成長率（CAGR）為5.2%。此外，生物材料、再生醫學和骨移植替代品的各種進步正在見證脊椎手術中越來越多的採用，從而積極增加脊椎生物製品的市場價值。

按手術類型分類：

開放式脊椎手術

微創脊椎手術

微創脊椎手術佔據業界最大佔有率

報告還根據手術類型對市場進行了詳細的細分和分析。這包括開放性脊椎手術和微創脊椎手術。報告稱，微創脊椎手術佔據最大的市場佔有率。

微創脊椎手術主要歸因於患者和醫療保健提供者對微創手術的日益偏好。微創脊椎手術與傳統開放性手術相比具有多種優勢，包括切口較小、失血量較少、住院時間較短、恢復時間較快。因此，它在治療各種脊椎疾病方面廣受歡迎，例如退化性椎間盤疾病、椎間盤突出、椎管狹窄和椎骨骨折。根據國家醫學圖書館的數據，微創脊椎 (MIS) 手術在影像導航系統、機器人和內視鏡檢查方面取得了顯著進展。美國每年完成超過 40 萬例病例，脊椎融合術是脊椎創傷、腫瘤、結構畸形和退化性疾病的常用和既定的治療選擇。

按最終用戶分類：

醫院

門診護理中心

脊椎手術中心

骨科診所

其他

醫院代表領先的細分市場

該報告提供了基於最終用戶的詳細市場細分和分析。這包括醫院、門診護理中心、脊椎手術中心、骨科診所等。報告稱，醫院佔最大部分。

醫院是專業醫療護理的主要中心，吸引了大量尋求治療多種形式脊椎疾病（包括需要手術的脊椎疾病）的患者。此外，一些醫院設有專門的脊椎中心或提供服務的科室，使其成為綜合來源護理的首選中心。除此之外，醫院與脊椎生物製品製造商和供應商有著強力的合作，從而提高了設備的效率。 2022 年 6 月，Xenco Medical 透過獲得美國食品藥物管理局 (FDA) 的許可並推出一次性使用的 Multilevel CerviKit，擴大了其用於門診手術中心的設備範圍。它包括一整套植入物和一次性器械，用於頸椎前路的二、三和四級手術。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔據最大的脊椎生物製品市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是脊椎生物製品最大的區域市場。

北美在市場上的主導地位可歸因於高度發展的醫療基礎設施、創新醫療技術的高採用率以及大量脊椎疾病患者。例如，根據國家脊髓損傷協會的資料，美國約有 45 萬人患有脊髓損傷 (SCI)。據估計，美國每年會出現 17,000 例新的 SCI 病例，主要源自於脊椎創傷。因此，SCI 族群發病率的增加顯著增加了該地區對脊椎生物製劑治療疾病的需求。此外，有利的報銷政策、強大的研發力度以及對微創外科手術優勢的認知正在為北美脊椎生物製劑市場帶來收入。

競爭格局：

脊椎生物製品市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。脊椎生物製品產業的一些主要市場參與者包括 Arthrex Inc.、Alphatec Holdings Inc.、Exactech Inc.、Johnson & Johnson、Medtronic plc、NuVasive Inc.、Orthofix Medical Inc.、Stryker Corporation、Wright Medical Group NV 和齊默比美特。

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

目前，市場上的主要參與者正在投資研究和創新，以開發優於競爭對手的模型並提供客戶尋求的解決方案。他們還努力透過發展策略聯盟、收購和擴展到新市場來滲透更多市場並滿足所有客戶需求，以確保其產品留在市場上並滿足客戶的需求。例如，2023 年 10 月，全球著名的脊椎和骨科公司 Orthofix Medical Inc. 在獲得 510k 許可後推出了 OsteoCove 的完整商業版本，這是一種創新的生物活性合成移植物。它以膩子和條狀形式提供，經過精心開發，可為各種脊柱和骨科手術提供卓越的成骨能力和最佳的操作性能。此外，出色的行銷和品牌管理也使其產品需求旺盛，這為脊椎生物製劑市場提供了積極的前景。

脊椎生物製劑市場新聞：

2022 年 8 月：Graftys SA 宣布續約與 Arthrex 的長期契約，涉及先進合成骨移植材料的多年供應協議。

2023 年 10 月：著名醫療技術公司 Stryker 推出了具有脊椎導引軟體的 Q 導引系統，該系統已部署用於為 2,400 多個脊椎病例提供改進的手術規劃和導航。

本報告回答的關鍵問題

  • 全球脊椎生物製劑市場有多大
  • 2024-2032年全球脊椎生物製劑市場的預期成長率是多少
  • 推動全球脊椎生物製品市場的關鍵因素是什麼
  • COVID-19 對全球脊椎生物製劑市場有何影響
  • 基於產品的全球脊椎生物製品市場的細分如何
  • 根據手術類型，全球脊椎生物製品市場的細分如何
  • 基於最終用戶的全球脊椎生物製品市場的細分是什麼
  • 全球脊椎生物製劑市場的關鍵區域有哪些
  • 誰是全球脊椎生物製品市場的主要參與者/公司

本報告回答的關鍵問題

  • 全球脊椎生物製劑市場有多大？ 2024-2032年全球脊椎生物製品市場的預期成長率是多少？
  • 推動全球脊椎生物製品市場的關鍵因素是什麼？
  • COVID-19 對全球脊椎生物製劑市場有何影響？
  • 基於該產品的全球脊椎生物製品市場的詳細情形如何？
  • 根據手術類型，全球脊椎生物製品市場的詳細情形如何？
  • 基於最終用戶的全球脊椎生物製品市場的詳細情形如何？
  • 全球脊椎生物製劑市場的關鍵區域有哪些？
  • 全球脊椎生物製品市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球脊椎生物製劑市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品

  • 同種異體脊椎移植物
    • 市場趨勢
    • 關鍵環節
      • 機械加工骨同種異體移植物
      • 去礦骨基質
    • 市場預測
  • 骨移植替代品
    • 市場趨勢
    • 關鍵環節
      • 骨形態發生蛋白
      • 合成骨移植物
    • 市場預測
  • 基於細胞的矩陣
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依手術類型

  • 開放式脊椎手術
    • 市場趨勢
    • 市場預測
  • 微創脊椎手術
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場趨勢
    • 市場預測
  • 門診護理中心
    • 市場趨勢
    • 市場預測
  • 脊椎手術中心
    • 市場趨勢
    • 市場預測
  • 骨科診所
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Arthrex Inc
    • Alphatec Holdings Inc.
    • Exactech Inc
    • Johnson & Johnson
    • Medtronic plc
    • NuVasive Inc
    • Orthofix Medical Inc.
    • Stryker Corporation
    • Wright Medical Group NV
    • Zimmer Biomet
Product Code: SR112024A4333

The global spine biologics market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The market is driven by the widespread adoption of minimally invasive surgeries (MIS), the growing geriatric population, the growing access to healthcare services on account of inflating income levels, and the increasing incidence of spinal disorders.

Spine Biologics Market Analysis:

Major Market Drivers: The spine biologics market research indicates that the market is primarily driven by the increasing prevalence of spinal disorders such as disc disease and spinal stenosis, often related to aging and lifestyle factors.

Key Market Trends: There is a noticeable trend toward the use of biologics in spine surgeries to promote quicker recovery and better outcomes, aligning with advancements in medical technologies. In the spine biologics market forecast, the industry will witness ongoing innovation with the integration of artificial intelligence and machine learning technologies to enhance the precision and effectiveness of spine biologics.

Geographical Trends: North America currently leads the global market due to its advanced healthcare infrastructure, high healthcare expenditure, and awareness of spinal ailments. Moreover, the Asia-Pacific region is witnessing rapid growth according to the spine biologics market statistics owing to increasing healthcare access, rising economic standards, and a growing geriatric population.

Competitive Landscape: Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet, among many others.

Challenges and Opportunities: The challenges in the market include concerns over the high cost of biologic products and stringent regulatory environments that can delay product launches. As outlined in the spine biologics market overview, the growing collaborations with insurance providers and healthcare facilities hold the potential to improve access to and uptake of biologic treatments generating numerous opportunities.

Spine Biologics Market Trends:

Increasing Prevalence of Spinal Disorders

The growing occurrence of spinal disorders is affecting the spine biologics market growth. In addition, the increasing life expectancy, and lifestyle issues, are spurring the development of degenerative illnesses such as disc disease and spinal stenosis. According to the World Health Organization (WHO) in 2020 approximately 1 in 13 individuals equating to 619 million individuals experienced low back pain (LBP), a 60% increase from 1990. It is further estimated that low back pain cases will increase by around 843 million by 2050 which emphasizes the widespread nature of spinal issues. The rising number of incidences is with the age group of 80 years, and the increasing number of LBP cases occur at the age of 50-55 years. This widespread prevalence necessitates ongoing development and deployment of effective treatments, including biologics, which help promote bone growth and healing, making them critical in treating these pervasive conditions.

Rising Adoption of Minimally Invasive Surgeries (MIS)

Minimally invasive surgeries (MIS) for spinal conditions are preferred due to their less distressful nature and quicker recovery times compared to traditional open surgeries. The global market for minimally invasive surgery is projected to expand at a compound annual growth rate (CAGR) of roughly 6% during 2024-2032 as per the IMARC GROUP. It reached US$ 52.9 Billion in 2023 and anticipates the market to reach US$ 91.0 Billion by 2032. This growth is declarative of a shift in surgical methods that reduce hospital stays and recovery periods, which is particularly beneficial for spine biologics market value.

Growing Geriatric Population

The growing geriatric population is driving the spine biologics market demand. As individuals age, the risk of developing spinal disorders increases, necessitating more frequent and intensive care. As per the data from the UNITED NATIONS population aged 65 and over is expected to rise from 10% in 2022 to 16% in 2050. It is forecasted that individuals aged 65 years or above globally will double the number of children under age 5 and will be equal to the number of 12-year-old children. It means a rising number of age-associated spinal conditions, escalating the demand for treatments that are effective and minimally invasive. For instance, biologics, which aid in the natural healing processes, are particularly suited to meet these needs, aligning with the growing healthcare requirements of an aging global population.

Spine Biologics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, surgery type, and end user.

Breakup by Product:

Spinal Allografts

Machined Bones Allograft

Demineralized Bone Matrix

Bone Graft Substitutes

Bone Morphogenetic Proteins

Synthetic Bone Grafts

Cell Based Matrix

Bone graft substitutes account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes spinal allografts (machined bones allograft, demineralized bone matrix), bone graft substitutes, (bone morphogenetic proteins, synthetic bone grafts), and cell-based matrix. According to the report, bone graft substitutes represented the largest segment.

Bone graft substitutes offer an alternative to customary bone grafts, stipulating structural support and facilitating bone healing processes in spinal surgeries. These substitutes embrace synthetic materials, allografts, and demineralized bone matrix, and are advocated for their aptitude to endorse bone fusion and curb the need for harvesting bone from the patient's own body, minimizing surgical complications and recovery time. As per the statistics by IMARC GROUP, the global bone graft and substitute market reached US$3.2 Billion in 2023. It is estimated to reach US$ 5.1 Billion by 2032 with a compound annual growth rate (CAGR) of 5.2% during 2024-2032. Moreover, various advancements in biomaterials, regenerative medicine, and bone graft substitutes are witnessing increasing adoption in spinal procedures, thus positively increasing the spine biologic market value.

Breakup by Surgery Type:

Open Spine Surgery

Minimally Invasive Spine Surgery

Minimally invasive spine surgery holds the largest share of the industry

A detailed breakup and analysis of the market based on the surgery type have also been provided in the report. This includes open spine surgery and minimally invasive spine surgery. According to the report, minimally invasive spine surgery accounted for the largest market share.

Minimally invasive spine surgery is primarily attributed to the growing preference for minimally invasive procedures among patients and healthcare providers. Minimally invasive spine surgery offers several advantages over traditional open surgeries, including smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times. As a result, it has gained popularity for treating various spinal conditions, such as degenerative disc disease, herniated discs, spinal stenosis, and vertebral fractures. According to the NATIONAL LIBRARY OF MEDICINE, minimally invasive spine (MIS) surgery has advanced significantly with imaging navigation systems, robotics, and endoscopy. More than 400,000 cases are accomplished in the United States annually with spine fusion being the commonly conducted and established treatment options for spine trauma, tumors, structural deformities, and degenerative disorders.

Breakup by End User:

Hospitals

Ambulatory Care Centers

Spinal Surgery Centers

Orthopedic Clinics

Others

Hospitals represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory care centers, spinal surgery centers, orthopedic clinics, and others. According to the report, hospitals represented the largest segment.

Hospitals are major centers for specialized medical care that attract a considerable proportion of patients seeking treatments for several forms of spinal disorders including those that necessitate surgeries. Furthermore, some hospitals have dedicated spine centers or departments where they offer services, making them the preferred centers for comprehensive source care. Besides this, hospitals have strong collaborations with spine biologic manufacturers and suppliers, thereby enhancing the efficiency of the equipment. In June 2022, Xenco Medical broadened its range of devices for ambulatory surgery centers by securing Food and Drug Administration (FDA) clearance and introducing its Multilevel CerviKit for their single use. It comprises a complete suite of implants and single-use instruments for two, three, and four level procedures of the anterior cervical spine.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest spine biologics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for spine biologics.

North America's dominance in the market can be attributed to highly developed healthcare infrastructure, the high rate of innovative medical technologies' adoption, and a large patient pool with spinal disorders. For instance, as per the data from the National Spinal Cord Injury Association, approximately 450,000 individuals reside in the United States with a spinal cord injury (SCI). Annually, an estimated 17,000 new cases of SCI arise in the U.S., predominantly stemming from trauma to the vertebral column. Thus, the increasing incidence of SCI population is significantly escalating the demand for spine biologics to treat disorders across the region. Additionally, favorable reimbursement policies, strong R&D efforts, and awareness of the advantages of minimally invasive surgical procedures are generating the spine biologics market revenue in North America.

Competitive Landscape:

The spine biologics market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

At present, key players in the market are investing in research and innovation to develop models that outperform rivals and offer solutions sought by customers. They also work hard to ensure their products remain in the market and meet customers' demands through the development of strategic alliances, acquisitions, and expansions into new markets to penetrate more markets and meet all customer needs. For instance, in October 2023, Orthofix Medical Inc., a prominent global spine and orthopedics corporation unveiled the full commercial release of OsteoCove, which is an innovative bioactive synthetic graft, following its 510k clearance. It is offered in putty and strip forms, meticulously developed to offer exceptional bone-forming capabilities and optimal handling properties for various spine and orthopedic procedures. Moreover, excellent marketing and brand management also make their products highly demanded, which is providing a positive spine biologics market outlook.

Spine Biologics Market News:

August 2022: Graftys SA announced the renewal of its lengthy contract with Arthrex for a multi-year supply agreement concerning advanced synthetic bone graft materials.

October 2023: Stryker, a prominent medical technology company unveiled their Q guidance system with spine guidance software which was deployed to supply improved surgical planning and navigation in over 2,400 spinal cases.

Key Questions Answered in This Report

  • 1. How big is the global spine biologics market?
  • 2. What is the expected growth rate of the global spine biologics market during 2024-2032?
  • 3. What are the key factors driving the global spine biologics market?
  • 4. What has been the impact of COVID-19 on the global spine biologics market?
  • 5. What is the breakup of the global spine biologics market based on the product?
  • 6. What is the breakup of the global spine biologics market based on the surgery type?
  • 7. What is the breakup of the global spine biologics market based on the end user?
  • 8. What are the key regions in the global spine biologics market?
  • 9. Who are the key players/companies in the global spine biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Spine Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Spinal Allografts
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Machined Bones Allograft
      • 6.1.2.2 Demineralized Bone Matrix
    • 6.1.3 Market Forecast
  • 6.2 Bone Graft Substitutes
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Bone Morphogenetic Proteins
      • 6.2.2.2 Synthetic Bone Grafts
    • 6.2.3 Market Forecast
  • 6.3 Cell Based Matrix
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Surgery Type

  • 7.1 Open Spine Surgery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Minimally Invasive Spine Surgery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Care Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Spinal Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Orthopedic Clinics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Arthrex Inc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Alphatec Holdings Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Exactech Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Johnson & Johnson
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Medtronic plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 NuVasive Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Orthofix Medical Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Stryker Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Wright Medical Group N.V.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Zimmer Biomet
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Spine Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Spine Biologics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Spine Biologics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Spine Biologics Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Spine Biologics Market: Breakup by Surgery Type (in %), 2023
  • Figure 6: Global: Spine Biologics Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Spine Biologics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Spine Biologics (Spinal Allografts) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Spine Biologics (Spinal Allografts) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Spine Biologics (Bone Graft Substitutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Spine Biologics (Bone Graft Substitutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Spine Biologics (Cell Based Matrix) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Spine Biologics (Cell Based Matrix) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Spine Biologics (Open Spine Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Spine Biologics (Open Spine Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Spine Biologics (Minimally Invasive Spine Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Spine Biologics (Minimally Invasive Spine Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Spine Biologics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Spine Biologics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Spine Biologics (Ambulatory Care Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Spine Biologics (Ambulatory Care Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Spine Biologics (Spinal Surgery Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Spine Biologics (Spinal Surgery Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Spine Biologics (Orthopedic Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Spine Biologics (Orthopedic Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Spine Biologics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Spine Biologics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Spine Biologics Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Spine Biologics Industry: SWOT Analysis
  • Figure 78: Global: Spine Biologics Industry: Value Chain Analysis
  • Figure 79: Global: Spine Biologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Spine Biologics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Spine Biologics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Spine Biologics Market Forecast: Breakup by Surgery Type (in Million US$), 2024-2032
  • Table 4: Global: Spine Biologics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Spine Biologics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Spine Biologics Market: Competitive Structure
  • Table 7: Global: Spine Biologics Market: Key Players